Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fresolimumab in Steroid-Resistant Primary FSGS
NCT01665391Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2012
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of fresolimumab in focal segmental glomerulosclerosis (FSGS), sponsored by Sanofi. Started Aug 2012; status: completed.
02
Drugs
fresolimumab
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT01665391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01665391.